October 1, 2024

Supplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

View Full Paper

Ask AI

Bookmark

Abstract

Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sudhakar et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efedb2 https://doi.org/10.1158/1535-7163.27142584

View Full Paper

Ask AI

Bookmark

Abstract

Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).